HBV replication inhibitors
Chronic Hepatitis B Virus infections afflict >250 million people and kill nearly 1 million annually. Current non-curative therapies are dominated by nucleos(t)ide analogs (NAs) that profoundly but incompletely suppress DNA synthesis by the viral reverse transcriptase. Residual HBV replication dur...
Saved in:
| Published in: | Antiviral research Vol. 179; p. 104815 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Elsevier B.V
01-07-2020
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Chronic Hepatitis B Virus infections afflict >250 million people and kill nearly 1 million annually. Current non-curative therapies are dominated by nucleos(t)ide analogs (NAs) that profoundly but incompletely suppress DNA synthesis by the viral reverse transcriptase. Residual HBV replication during NA therapy contributes to maintenance of the critical nuclear reservoir of the HBV genome, the covalently-closed circular DNA, and to ongoing infection of naive cells. Identification of next-generation NAs with improved efficacy and safety profiles, often through novel prodrug approaches, is the primary thrust of ongoing efforts to improve HBV replication inhibitors. Inhibitors of the HBV ribonuclease H, the other viral enzymatic activity essential for viral genomic replication, are in preclinical development. The complexity of HBV's reverse transcription pathway offers many other potential targets. HBV's protein-priming of reverse transcription has been briefly explored as a potential target, as have the host chaperones necessary for function of the HBV reverse transcriptase. Improved inhibitors of HBV reverse transcription would reduce HBV's replication-dependent persistence mechanisms and are therefore expected to become a backbone of future curative combination anti-HBV therapies.
•NA inhibitors currently dominate HBV therapy.•Improvement of NAs focuses on efficacy, safety, resistance and prodrug delivery.•HBV ribonuclease inhibitors are in preclinical development.•Other approaches for directly inhibiting HBV reverse transcription are possible. |
|---|---|
| AbstractList | Chronic Hepatitis B Virus infections afflict >250 million people and kill nearly 1 million annually. Current non-curative therapies are dominated by nucleos(t)ide analogs (NAs) that profoundly but incompletely suppress DNA synthesis by the viral reverse transcriptase. Residual HBV replication during NA therapy contributes to maintenance of the critical nuclear reservoir of the HBV genome, the covalently-closed circular DNA, and to ongoing infection of naive cells. Identification of next-generation NAs with improved efficacy and safety profiles, often through novel prodrug approaches, is the primary thrust of ongoing efforts to improve HBV replication inhibitors. Inhibitors of the HBV ribonuclease H, the other viral enzymatic activity essential for viral genomic replication, are in preclinical development. The complexity of HBV’s reverse transcription pathway offers many other potential targets. HBV’s protein-priming of reverse transcription has been briefly explored as a potential target, as have the host chaperones necessary for function of the HBV reverse transcriptase. Improved inhibitors of HBV reverse transcription would reduce HBV’s replication-dependent persistence mechanisms and are therefore expected to become a backbone of future curative combination anti-HBV therapies. Chronic Hepatitis B Virus infections afflict >250 million people and kill nearly 1 million annually. Current non-curative therapies are dominated by nucleos(t)ide analogs (NAs) that profoundly but incompletely suppress DNA synthesis by the viral reverse transcriptase. Residual HBV replication during NA therapy contributes to maintenance of the critical nuclear reservoir of the HBV genome, the covalently-closed circular DNA, and to ongoing infection of naive cells. Identification of next-generation NAs with improved efficacy and safety profiles, often through novel prodrug approaches, is the primary thrust of ongoing efforts to improve HBV replication inhibitors. Inhibitors of the HBV ribonuclease H, the other viral enzymatic activity essential for viral genomic replication, are in preclinical development. The complexity of HBV's reverse transcription pathway offers many other potential targets. HBV's protein-priming of reverse transcription has been briefly explored as a potential target, as have the host chaperones necessary for function of the HBV reverse transcriptase. Improved inhibitors of HBV reverse transcription would reduce HBV's replication-dependent persistence mechanisms and are therefore expected to become a backbone of future curative combination anti-HBV therapies. •NA inhibitors currently dominate HBV therapy.•Improvement of NAs focuses on efficacy, safety, resistance and prodrug delivery.•HBV ribonuclease inhibitors are in preclinical development.•Other approaches for directly inhibiting HBV reverse transcription are possible. |
| ArticleNumber | 104815 |
| Author | Dousson, Cyril B. Pierra Rouviere, Claire Tavis, John E. |
| AuthorAffiliation | b Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO USA a Ai-biopharma, Medicinal Chemistry Department, Montpellier, France |
| AuthorAffiliation_xml | – name: b Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO USA – name: a Ai-biopharma, Medicinal Chemistry Department, Montpellier, France |
| Author_xml | – sequence: 1 givenname: Claire surname: Pierra Rouviere fullname: Pierra Rouviere, Claire organization: Ai-biopharma, Medicinal Chemistry Department, Montpellier, France – sequence: 2 givenname: Cyril B. orcidid: 0000-0002-6046-5032 surname: Dousson fullname: Dousson, Cyril B. email: cyril.dousson@ai-biopharma.com organization: Ai-biopharma, Medicinal Chemistry Department, Montpellier, France – sequence: 3 givenname: John E. surname: Tavis fullname: Tavis, John E. email: John.tavis@health.slu.edu organization: Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32380149$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkE1PAyEURYnRaKv-ARfq0s1UvmaAjYkavxITN-qWMMxDaaZQYdrEfy9NtdGVKxI4797HGaPtEAMgdELwhGDSnE8nJgx-6ZPpJxTT1S2XpN5CIyIFrRRWzTYaFbKpWM3pHhrnPMUYN0LJXbTHKJOYcDVCR_dXr6cJ5r23ZvAxnPrw7ls_xJQP0I4zfYbD73MfvdzePF_fV49Pdw_Xl4-V5aIeqhZjw7CT4ARzUrWipcCoMVYKR1zdNY52UoHiltGaF7qWDSjXcOhci41k--hinTtftDPoLIShfEvPk5-Z9Kmj8frvS_Dv-i0utaCK1YKWgLPvgBQ_FpAHPfPZQt-bAHGRNeWllKuG4IKKNWpTzDmB29QQrFdm9VRvzOqVWb02WyaPf2-5mftRWYDLNQDF1dJD0tl6CBY6n8AOuov-35IvPTCQQw |
| CitedBy_id | crossref_primary_10_1021_acs_jmedchem_0c01381 crossref_primary_10_3390_ph14050417 crossref_primary_10_3390_vaccines10020257 crossref_primary_10_4254_wjh_v15_i5_585 crossref_primary_10_1016_j_antiviral_2022_105515 crossref_primary_10_3389_fimmu_2022_1024333 crossref_primary_10_1053_j_gastro_2022_10_008 crossref_primary_10_3390_ijms232415973 crossref_primary_10_1016_j_bmcl_2023_129412 crossref_primary_10_1016_j_jviromet_2021_114127 crossref_primary_10_3389_fcell_2021_717610 crossref_primary_10_3390_biomedicines9111577 crossref_primary_10_3748_wjg_v28_i27_3282 crossref_primary_10_3390_molecules29122942 crossref_primary_10_1002_chem_202104112 crossref_primary_10_1016_j_molliq_2022_119029 crossref_primary_10_1097_HC9_0000000000000205 crossref_primary_10_1080_17474124_2023_2268503 crossref_primary_10_1016_j_jhep_2021_01_038 crossref_primary_10_1021_acs_jmedchem_2c00667 crossref_primary_10_3389_fimmu_2022_970130 crossref_primary_10_1128_AAC_01617_21 crossref_primary_10_1002_jmv_29439 crossref_primary_10_1111_apt_16828 crossref_primary_10_1002_pro_4421 crossref_primary_10_1080_17460441_2023_2192920 crossref_primary_10_1128_AAC_01460_21 crossref_primary_10_3389_fcimb_2023_1128807 crossref_primary_10_1128_AAC_01220_21 crossref_primary_10_1016_j_biopha_2023_114904 crossref_primary_10_1080_14740338_2022_2045271 crossref_primary_10_1016_j_virs_2022_01_027 crossref_primary_10_1039_D2BM00407K |
| Cites_doi | 10.1515/ii-2017-0010 10.1016/j.antiviral.2014.01.009 10.1016/0092-8674(82)90157-X 10.1128/AAC.04617-14 10.1016/j.jhep.2016.02.012 10.1021/acsmedchemlett.9b00184 10.1007/s00535-019-01643-0 10.1021/mp3002045 10.1007/s12072-019-09989-6 10.3390/molecules15095878 10.1016/j.cgh.2018.11.001 10.1177/2040206618775243 10.1016/j.cgh.2013.01.026 10.1111/liv.13059 10.1002/hep.23462 10.1016/j.antiviral.2017.04.012 10.1128/AAC.00599-13 10.1111/hiv.12401 10.1021/acs.joc.8b02599 10.1016/S0168-8278(06)80742-7 10.1016/j.antiviral.2017.11.008 10.1136/gutjnl-2015-309300 10.1002/hep.29509 10.1002/med.21490 10.1056/NEJMoa0802878 10.1126/science.1707186 10.1002/hep.29323 10.1111/j.1440-1746.2011.06766.x 10.1021/acsomega.8b01754 10.1007/s12072-017-9797-y 10.1016/j.antiviral.2019.02.005 10.1016/j.antiviral.2014.05.007 10.1021/jm7012216 10.1128/AAC.00263-09 10.1128/JVI.02147-07 10.1016/S2468-1253(16)30024-3 10.1128/AAC.01566-05 10.3346/jkms.2017.32.11.1857 10.1177/1756284818786108 10.1016/j.ejphar.2012.02.030 10.1111/liv.12057 10.3851/IMP1510 10.1038/nrgastro.2016.7 10.1128/AAC.01764-09 10.1002/hep.23327 10.1177/135965350801300206 10.1093/nar/gkg881 10.1016/S2468-1253(18)30056-6 10.3851/IMP2770 10.3748/wjg.v21.i44.12558 10.1007/s12072-016-9737-2 10.1053/j.gastro.2009.08.063 10.1038/s41598-018-27890-4 10.1136/gutjnl-2013-305138 10.1016/j.jhep.2014.10.035 10.1159/000360947 10.1016/j.jhep.2014.10.026 10.4254/wjh.v6.i6.384 10.3748/wjg.v20.i24.7707 10.1016/j.antiviral.2004.07.003 10.1016/j.biocel.2012.04.006 10.3390/biology1030521 10.1016/j.jhep.2017.03.021 10.1016/j.antiviral.2019.104693 10.1038/ajg.2009.726 10.1016/S0140-6736(12)61425-1 10.1128/JVI.68.6.3536-3543.1994 10.1016/j.antiviral.2016.06.005 10.1016/S2468-1253(16)30107-8 10.1002/hep.28280 10.1371/journal.ppat.1003125 10.1007/s12072-016-9745-2 10.1111/j.1365-2893.2010.01321.x 10.1016/j.jhep.2018.08.012 10.1016/S0140-6736(14)60220-8 10.1128/AAC.00128-15 10.1016/S2468-1253(19)30119-0 10.2174/0929867321666140120121158 10.1128/AAC.02441-16 10.1007/s00535-020-01680-0 10.1128/AAC.00460-07 10.1016/S2055-6640(20)30248-X 10.1358/dot.2009.45.5.1377596 10.1053/j.gastro.2007.02.039 10.1007/s12072-020-10024-2 10.1016/j.cgh.2019.08.033 10.1016/j.jhep.2016.08.022 10.1016/j.antiviral.2013.06.007 10.1002/hep.28156 10.1016/j.antiviral.2016.09.009 10.1128/AAC.02574-16 10.1111/jvh.12613 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier B.V. Copyright © 2020 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Copyright © 2020 Elsevier B.V. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1016/j.antiviral.2020.104815 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1872-9096 |
| EndPage | 104815 |
| ExternalDocumentID | 10_1016_j_antiviral_2020_104815 32380149 S0166354220302291 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Review Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R21 AI124672 – fundername: NIAID NIH HHS grantid: R01 AI122669 |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 1B1 1RT 1~. 1~5 23M 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATCM AAXUO ABBQC ABFNM ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ABZDS ACDAQ ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AFFNX AFKWA AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CJTIS CNWQP CS3 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMG HVGLF HZ~ IHE J1W KOM LCYCR LUGTX M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SIN SPCBC SSH SSI SSP SSZ T5K TEORI WUQ ZGI ZXP ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c475t-b00a30f8ef73f89b7b2e32aac87f1f5d6f2d89e94c3254b00586e9f64edfb0a83 |
| ISSN | 0166-3542 |
| IngestDate | Tue Sep 17 21:17:07 EDT 2024 Sat Oct 05 05:47:33 EDT 2024 Thu Sep 26 17:15:23 EDT 2024 Sat Sep 28 08:33:45 EDT 2024 Fri Feb 23 02:46:42 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Reverse transcriptase inhibitors Ribonuclease H inhibitors Hepatitis B virus Chronic hepatitis B Nucleos(t)ide analogs |
| Language | English |
| License | Copyright © 2020 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c475t-b00a30f8ef73f89b7b2e32aac87f1f5d6f2d89e94c3254b00586e9f64edfb0a83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-2 |
| ORCID | 0000-0002-6046-5032 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/am/pii/S0166354220302291 |
| PMID | 32380149 |
| PQID | 2400549610 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7293572 proquest_miscellaneous_2400549610 crossref_primary_10_1016_j_antiviral_2020_104815 pubmed_primary_32380149 elsevier_sciencedirect_doi_10_1016_j_antiviral_2020_104815 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-01 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Antiviral research |
| PublicationTitleAlternate | Antiviral Res |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Reddy, Matelich, Ugarkar, Gomez-Galeno, DaRe, Ollis, Sun, Craigo, Colby, Fujitaki, Boyer, van Poelje, Erion (bib75) 2008; 51 Lin, Fang, Benetton, Xu, Yeh (bib50) 2006; 50 Revill, Chisari, Block, Dandri, Gehring, Guo, Hu, Kramvis, Lampertico, Janssen, Levrero, Li, Liang, Lim, Lu, Penicaud, Tavis, Thimme, Members of the ICE-HBV Working Group, ICE-HBV Stakeholder Chairs, ICE-HBV Senior Advisors, Zoulim (bib77) 2019; 4 De La Rosa, Painter, Bluemling (bib25) 2017 Liaw (bib49) 2019; 13 World Health Organization (bib99) 2019 Kim (bib40) 2018; 14 Omoto, Speranzini, Hashimoto, Noshi, Yamaguchi, Kawai, Kawaguchi, Uehara, Shishido, Naito, Cusack (bib69) 2018; 8 Zhou, Wang, Zhang, Zheng, Yang, Wang, Jiang, Ma, Yin, Sun, Wang (bib109) 2012; 683 Villa, Pike, Patel, Lomonosova, Lu, Abdulqader, Tavis (bib91) 2016; 132 Byrne, Carey, Agarwal (bib12) 2018; 11 (bib21) 2020 Murakami, Melda Urekli, Atta (bib65) 2014; 60 Kim, Kim, Seong (bib39) 2010; 15 Wang, Liu, He, Han, Peng, Li, You, Song, Li, Yu, Cen, Hong, Sun, Zhao, Kreiswirth, Perlin, Shao, Jiang (bib97) 2010; 54 Yi, S., Chen, D., Liu, H., Wang, Y., Jia, J., Luo, J., Hui, S., 2017a. Alkylalkoxy Ester Produg of Nuleoside Analogue and Use Thereof, China patent WO2017124895. Yip, Lok (bib103) 2019; 18 Marcellin, Gane, Buti, Afdhal, Sievert, Jacobson, Washington, Germanidis, Flaherty, Aguilar Schall, Bornstein, Kitrinos, Subramanian, McHutchison, Heathcote (bib60) 2013; 381 Tavis, Cheng, Hu, Totten, Cao, Michailidis, Aurora, Meyers, Jacobsen, Parniak, Sarafianos (bib85) 2013; 9 Wang, Zhang, Zhu, Xiong, Wang (bib93) 2014; 103 Murakami, Wang, Park, Hao, Lepist, Babusis, Ray (bib66) 2015; 59 Buti, Gane, Seto, Chan, Chuang, Stepanova, Hui, Lim, Mehta, Janssen, Acharya, Flaherty, Massetto, Cathcart, Kim, Gaggar, Subramanian, McHutchison, Pan, Brunetto, Izumi, Marcellin, Investigators (bib11) 2016; 1 Lu, Lomonosova, Cheng, Moran, Meyers, Le Grice, Thomas, Jiang, Meck, Hirsch, D'Erasmo, Suyabatmaz, Murelli, Tavis (bib57) 2015; 59 Wang, Wu, Tao, Li, Lv, Ma, Li, Li, Liu (bib92) 2019; 10 Ilina, Labarge, Sarafianos, Ishima, Parniak (bib36) 2012; 1 Anderson (bib5) 2009; 45 Chan, Fung, Seto, Chuang, Chen, Kim, Hui, Janssen, Chowdhury, Tsang, Mehta, Gane, Flaherty, Massetto, Gaggar, Kitrinos, Lin, Subramanian, McHutchison, Lim, Acharya, Agarwal, Investigators (bib16) 2016; 1 Lin, Hu (bib51) 2008; 82 Park, Kim, Bae, Jung, Kim, Yoon (bib71) 2016; 36 Lee, Park, Kim, Nguyen, Hong, Kim, Chon, Han, Ahn (bib46) 2010; 15 Lee, Lim, Chuang, Hwang, Cho, Lai, Chao, Chang, Han, Lee, Um, Yeon, Yang, Teo, Peng, Lin, Huo, Nguyen, Chen, Hu, Xu, Sullivan-Bolyai, Lee (bib47) 2006; 44 Seeger, Zoulim, Mason (bib79) 2013 Singh, Mulamoottil, Chu (bib81) 2019; 84 Klumpp, Hang, Rajendran, Yang, Derosier, Wong, Overton, Parkes, Cammack, Martin (bib41) 2003; 31 Lomonosova, Zlotnick, Tavis (bib55) 2017; 61 Antela, Aguiar, Compston, Hendry, Boffito, Mallon, Pourcher-Martinez, Di Perri (bib6) 2016; 17 Liaw (bib48) 2013; 33 Zhang, Liu, Li, Jin, Wu, Li, Liu, Junqi, Ding (bib106) 2020; 174 Ghany, Liang (bib31) 2007; 132 Wong, Seto, Fung, Ip, Huang, Lai, Yuen (bib98) 2013; 11 Babusis, Phan, Lee, Watkins, Ray (bib8) 2013; 10 Edwards, Mani, Dorsey, Kakarla, Rijnbrand, Sofia, Tavis (bib30) 2019; 164 EASL (bib28) 2017; 67 Lok, McMahon, Brown, Wong, Ahmed, Farah, Almasri, Alahdab, Benkhadra, Mouchli, Singh, Mohamed, Abu Dabrh, Prokop, Wang, Murad, Mohammed (bib53) 2016; 63 Monto, Schooley, Lai, Sulkowski, Chung, Pawlotsky, McHutchison, Jacobson (bib64) 2010; 105 Coffin, Mulrooney-Cousins, Peters, van Marle, Roberts, Michalak, Terrault (bib22) 2011; 18 Ahn, Kim, Jung, Yang, Jang, Kweon, Um, Sohn, Lee, Park, Lee, Kim, Kim, Yoon, Kim, Yim, Lee, Lim, Lee, Park, Jin, Kim, Choi, Han (bib2) 2019; 17 Painter, Almond, Trost, Lampert, Neyts, De Clercq, Korba, Aldern, Beadle, Hostetler (bib70) 2007; 51 Marcellin, Heathcote, Buti, Gane, de Man, Krastev, Germanidis, Lee, Flisiak, Kaita, Manns, Kotzev, Tchernev, Buggisch, Weilert, Kurdas, Shiffman, Trinh, Washington, Sorbel, Anderson, Snow-Lampart, Mondou, Quinn, Rousseau (bib61) 2008; 359 Revill, Testoni, Locarnini, Zoulim (bib76) 2016; 13 (bib74) 2018; 3 Chang, Lai, Kew Yoon, Lee, Coelho, Carrilho, Poordad, Halota, Horsmans, Tsai, Zhang, Tenney, Tamez, Iloeje (bib17) 2010; 51 Agarwal, Fung, Nguyen, Cheng, Sicard, Ryder, Flaherty, Lawson, Zhao, Subramanian, McHutchison, Gane, Foster (bib1) 2015; 62 Ko, Chakraborty, Chou, Hasreiter, Wettengel, Stadler, Bester, Asen, Zhang, Wisskirchen, McKeating, Ryu, Protzer (bib42) 2018; 69 Lai, Wong, Ip (bib45) 2017; 66 Sagnelli, Pisaturo, Martini, Filippini, Sagnelli, Coppola (bib78) 2014; 6 Lu, Villa, Donlin, Edwards, Cheng, Heier, Meyers, Tavis (bib58) 2016; 135 Yi, S., He, Y., Xiao, N., Pan, X., Luo, J., Hui, S., 2017b. Phosphate Prodrug of Nucleoside Analogue and Use Thereof, China Patent WO2017124896. Cai, Lomonosova, Moran, Cheng, Patel, Bailly, Cotelle, Meyers, Tavis (bib13) 2014; 108 Zoulim (bib111) 2004; 64 Yuen, Ahn, Lee, Um, Cho, Yoon, Lee, Park, Kweon, Sohn, Lee, Kim, Lai, Han (bib104) 2015; 62 Yuen, Han, Um, Yoon, Kim, Kim, Kim, Lai (bib105) 2010; 51 Lai, Ahn, Lee, Um, Cho, Yoon, Lee, Park, Kweon, Sohn, Lee, Kim, Han, Yuen (bib44) 2014; 63 Wang, Chen (bib94) 2014; 20 (bib7) 2010; 14 Edwards, Lomonosova, Patel, Li, Villa, Gupta, Morrison, Bailly, Cotelle, Giannakopoulou, Zoidis, Tavis (bib29) 2017; 143 Honghai, L., 2019. Tenofovir Diester Compounds and Salts Thereof, Preparation Method and Medicine Application of Compounds, China patent CN109400647 A. Zhijian, X., Huaqiang, X., Chunping, L., Zhongshan, W., 2019a. Liver specific delivery-based entecavir prodrug, nucleoside cyclic phosphate compound, and application thereof, International Patent WO2019120301 A1. Trepo, Chan, Lok (bib90) 2014; 384 Kramvis (bib43) 2014; 57 Chatsiricharoenkul, Tanwandee, Matkovits, Conover, Cobb, Canizares, Sullivan-Bolyai (bib18) 2017; 11 Tillmann (bib89) 2007; 8 Niu, Murakami, Furman (bib68) 2008; 13 Huber, Michailidis, Tang, Puray-Chavez, Boftsi, Wolf, Boschert, Sheridan, Leslie, Kirby, Singh, Mitsuya, Parniak, Wang, Sarafianos (bib35) 2017; 61 (bib20) 2013 Long, Lomonosova, Li, Ponzar, Villa, Touchette, Rapp, Liley, Murelli, Grigoryan, Buller, Wilson, Bial, Sagartz, Tavis (bib56) 2018; 149 Tavis, Perri, Ganem (bib86) 1994; 68 Tian, Jia (bib88) 2016; 10 Zhijian, X., Huaqiang, X., Chunping, L., Zhongshan, W., Feng, S., Zhenwei, Z., 2019b. Liver Specific Delivery-Based Antiviral Prodrug Nucleoside Cyclophosphate Compound and Uses Thereof, USA Patent US2019125771 A1. Jia, Deng, Tong, Li, Ren, Yin (bib37) 2020 Zhuorong, L., Zongying, L., Hong, Y., Yanping, L., 2012. Preparation Method of Acyclic Nucleoside Antiviral Drug Phosphoric Acid Monoester Compound. China Patent CN102417521. Takkenberg, Terpstra, Zaaijer, Weegink, Dijkgraaf, Jansen, Beld, Reesink (bib84) 2011; 26 Ding, Zhang, Li, Li, Chen, Chen, Wu, Niu (bib26) 2017; 11 Cheng, Quan, Liu, Wang (bib19) 2012; 1 Wang, Y., Zhao, J., 2019a. Antiviral nuleoside reverse transcriptase inhibitor, International Patent WO2019120084 A1. Zoulim, Locarnini (bib113) 2009; 137 Jones, Murakami, Delaney, Furman, Hu (bib38) 2013; 57 Liu, Corsa, Buti, Cathcart, Flaherty, Miller, Kitrinos, Marcellin, Gane (bib52) 2017; 24 Cao, Song, De Clercq, Zhan, Liu (bib15) 2014; 21 Donlin, Zunica, Lipnicky, Garimallaprabhakaran, Berkowitz, Grigoryan, Meyers, Tavis, Murelli (bib27) 2017; 61 Hu, Cheng, Cao, Huang, Tavis (bib34) 2013; 99 Zoulim, Bialkowska-Warzecha, Diculescu, Goldis, Heyne, Mach (bib112) 2016; 10 Bayliss, Yuen, Rosenberg, Wong, Littlejohn, Jackson, Gaggar, Kitrinos, Subramanian, Marcellin, Buti, Janssen, Gane, Sozzi, Colledge, Hammond, Edwards, Locarnini, Thompson, Revill (bib10) 2017; 66 Cao, Orth, Donlin, Adegboyega, Meyers, Murelli, Elagawany, Elgendy, Tavis (bib14) 2018; 3 Michailidis, Kirby, Hachiya, Yoo, Hong, Kim, Folk, Sarafianos (bib62) 2012; 44 Singh, Mulamoottil, Chu (bib80) 2018; 38 Terrault, Bzowej, Chang, Hwang, Jonas, Murad (bib87) 2016; 63 Alter, Block, Brown, Brownstein, Brosgart, Chang, Chen, Chisari, Cohen, El-Serag, Feld, Gish, Glenn, Greten, Guo, Guo, Hoshida, Hu, Kowdley, Li, Liang, Locarnini, Lok, Mason, McMahon, Mehta, Perrillo, Revill, Rice, Rinaudo, Schinazi, Seeger, Shetty, Tavis, Zoulim (bib4) 2017; 67 Park, Park, Kim, Cho, Koh, Lee (bib72) 2017; 32 de Fraga, Van Vaisberg, Mendes, Carrilho, Ono (bib24) 2020; 55 Summers, Mason (bib83) 1982; 29 Slusarczyk, Serpi, Pertusati (bib82) 2018; 26 Michalak, Zhang, Churchill, Larsson, Johansson, Oberg (bib63) 2009; 53 Xinglu, Z., Xingguo, L., Miao, H., Xiaowu, D., Wenhai, H., 2019. Phosphoramidate Prodrug of Nucleoside Analogues, a Pharmaceutical Composition and Applications of the Phosphoramidate Prodrug, China Patent CN109535200 A. Lok, Zoulim, Dusheiko, Ghany (bib54) 2017; 66 Manzoor, Saalim, Imran, Resham, Ashraf (bib59) 2015; 21 Bam, Yant, Cihlar (bib9) 2014; 19 Davies, Hostomska, Hostomsky, Jordan, Matthews (bib23) 1991; 252 Hill, Hughes, Gotham, Pozniak (bib32) 2018; 4 Allweiss, Dandri (bib3) 2016; 64 Nakajima, Watashi, Fukano, Tsukuda, Wakae, Aizaki, Muramatsu, Wakita, Toyoda (bib67) 2019; 55 Peters, Locarnini (bib73) 2017; 13 Wang, Y., Zhao, J., 2019b. Novel antiviral nucleoside reverse transcriptase inhibitor, International Patent WO2019120071 A1. Byrne (10.1016/j.antiviral.2020.104815_bib12) 2018; 11 Ilina (10.1016/j.antiviral.2020.104815_bib36) 2012; 1 Painter (10.1016/j.antiviral.2020.104815_bib70) 2007; 51 EASL (10.1016/j.antiviral.2020.104815_bib28) 2017; 67 Donlin (10.1016/j.antiviral.2020.104815_bib27) 2017; 61 Liaw (10.1016/j.antiviral.2020.104815_bib49) 2019; 13 Bayliss (10.1016/j.antiviral.2020.104815_bib10) 2017; 66 Chang (10.1016/j.antiviral.2020.104815_bib17) 2010; 51 10.1016/j.antiviral.2020.104815_bib33 Omoto (10.1016/j.antiviral.2020.104815_bib69) 2018; 8 (10.1016/j.antiviral.2020.104815_bib74) 2018; 3 Zoulim (10.1016/j.antiviral.2020.104815_bib111) 2004; 64 Tavis (10.1016/j.antiviral.2020.104815_bib85) 2013; 9 Chan (10.1016/j.antiviral.2020.104815_bib16) 2016; 1 Ko (10.1016/j.antiviral.2020.104815_bib42) 2018; 69 Klumpp (10.1016/j.antiviral.2020.104815_bib41) 2003; 31 Long (10.1016/j.antiviral.2020.104815_bib56) 2018; 149 Park (10.1016/j.antiviral.2020.104815_bib71) 2016; 36 Yip (10.1016/j.antiviral.2020.104815_bib103) 2019; 18 de Fraga (10.1016/j.antiviral.2020.104815_bib24) 2020; 55 (10.1016/j.antiviral.2020.104815_bib20) 2013 Hu (10.1016/j.antiviral.2020.104815_bib34) 2013; 99 Lok (10.1016/j.antiviral.2020.104815_bib53) 2016; 63 Seeger (10.1016/j.antiviral.2020.104815_bib79) 2013 Murakami (10.1016/j.antiviral.2020.104815_bib66) 2015; 59 Revill (10.1016/j.antiviral.2020.104815_bib77) 2019; 4 World Health Organization (10.1016/j.antiviral.2020.104815_bib99) 2019 Cao (10.1016/j.antiviral.2020.104815_bib15) 2014; 21 Jia (10.1016/j.antiviral.2020.104815_bib37) 2020 Sagnelli (10.1016/j.antiviral.2020.104815_bib78) 2014; 6 Niu (10.1016/j.antiviral.2020.104815_bib68) 2008; 13 Huber (10.1016/j.antiviral.2020.104815_bib35) 2017; 61 Liaw (10.1016/j.antiviral.2020.104815_bib48) 2013; 33 Cai (10.1016/j.antiviral.2020.104815_bib13) 2014; 108 Edwards (10.1016/j.antiviral.2020.104815_bib30) 2019; 164 Lin (10.1016/j.antiviral.2020.104815_bib51) 2008; 82 Alter (10.1016/j.antiviral.2020.104815_bib4) 2017; 67 Lai (10.1016/j.antiviral.2020.104815_bib45) 2017; 66 Kim (10.1016/j.antiviral.2020.104815_bib39) 2010; 15 Nakajima (10.1016/j.antiviral.2020.104815_bib67) 2019; 55 Kim (10.1016/j.antiviral.2020.104815_bib40) 2018; 14 10.1016/j.antiviral.2020.104815_bib110 Ghany (10.1016/j.antiviral.2020.104815_bib31) 2007; 132 Lomonosova (10.1016/j.antiviral.2020.104815_bib55) 2017; 61 Bam (10.1016/j.antiviral.2020.104815_bib9) 2014; 19 Tillmann (10.1016/j.antiviral.2020.104815_bib89) 2007; 8 Lin (10.1016/j.antiviral.2020.104815_bib50) 2006; 50 Agarwal (10.1016/j.antiviral.2020.104815_bib1) 2015; 62 (10.1016/j.antiviral.2020.104815_bib21) 2020 Michailidis (10.1016/j.antiviral.2020.104815_bib62) 2012; 44 Villa (10.1016/j.antiviral.2020.104815_bib91) 2016; 132 Jones (10.1016/j.antiviral.2020.104815_bib38) 2013; 57 Wang (10.1016/j.antiviral.2020.104815_bib97) 2010; 54 Lee (10.1016/j.antiviral.2020.104815_bib47) 2006; 44 Zoulim (10.1016/j.antiviral.2020.104815_bib112) 2016; 10 Cao (10.1016/j.antiviral.2020.104815_bib14) 2018; 3 10.1016/j.antiviral.2020.104815_bib108 Lee (10.1016/j.antiviral.2020.104815_bib46) 2010; 15 10.1016/j.antiviral.2020.104815_bib107 Wang (10.1016/j.antiviral.2020.104815_bib94) 2014; 20 Marcellin (10.1016/j.antiviral.2020.104815_bib60) 2013; 381 Zhang (10.1016/j.antiviral.2020.104815_bib106) 2020; 174 Tavis (10.1016/j.antiviral.2020.104815_bib86) 1994; 68 10.1016/j.antiviral.2020.104815_bib102 10.1016/j.antiviral.2020.104815_bib101 10.1016/j.antiviral.2020.104815_bib100 Lok (10.1016/j.antiviral.2020.104815_bib54) 2017; 66 Allweiss (10.1016/j.antiviral.2020.104815_bib3) 2016; 64 Buti (10.1016/j.antiviral.2020.104815_bib11) 2016; 1 Monto (10.1016/j.antiviral.2020.104815_bib64) 2010; 105 Kramvis (10.1016/j.antiviral.2020.104815_bib43) 2014; 57 Ahn (10.1016/j.antiviral.2020.104815_bib2) 2019; 17 Wong (10.1016/j.antiviral.2020.104815_bib98) 2013; 11 Michalak (10.1016/j.antiviral.2020.104815_bib63) 2009; 53 Singh (10.1016/j.antiviral.2020.104815_bib80) 2018; 38 Terrault (10.1016/j.antiviral.2020.104815_bib87) 2016; 63 Wang (10.1016/j.antiviral.2020.104815_bib93) 2014; 103 Antela (10.1016/j.antiviral.2020.104815_bib6) 2016; 17 Yuen (10.1016/j.antiviral.2020.104815_bib104) 2015; 62 Wang (10.1016/j.antiviral.2020.104815_bib92) 2019; 10 Lu (10.1016/j.antiviral.2020.104815_bib57) 2015; 59 Tian (10.1016/j.antiviral.2020.104815_bib88) 2016; 10 Manzoor (10.1016/j.antiviral.2020.104815_bib59) 2015; 21 Singh (10.1016/j.antiviral.2020.104815_bib81) 2019; 84 Davies (10.1016/j.antiviral.2020.104815_bib23) 1991; 252 Ding (10.1016/j.antiviral.2020.104815_bib26) 2017; 11 Takkenberg (10.1016/j.antiviral.2020.104815_bib84) 2011; 26 Babusis (10.1016/j.antiviral.2020.104815_bib8) 2013; 10 Marcellin (10.1016/j.antiviral.2020.104815_bib61) 2008; 359 Zhou (10.1016/j.antiviral.2020.104815_bib109) 2012; 683 Liu (10.1016/j.antiviral.2020.104815_bib52) 2017; 24 Peters (10.1016/j.antiviral.2020.104815_bib73) 2017; 13 Summers (10.1016/j.antiviral.2020.104815_bib83) 1982; 29 Edwards (10.1016/j.antiviral.2020.104815_bib29) 2017; 143 10.1016/j.antiviral.2020.104815_bib96 Zoulim (10.1016/j.antiviral.2020.104815_bib113) 2009; 137 10.1016/j.antiviral.2020.104815_bib95 Murakami (10.1016/j.antiviral.2020.104815_bib65) 2014; 60 Revill (10.1016/j.antiviral.2020.104815_bib76) 2016; 13 Trepo (10.1016/j.antiviral.2020.104815_bib90) 2014; 384 Chatsiricharoenkul (10.1016/j.antiviral.2020.104815_bib18) 2017; 11 De La Rosa (10.1016/j.antiviral.2020.104815_bib25) 2017 Park (10.1016/j.antiviral.2020.104815_bib72) 2017; 32 Yuen (10.1016/j.antiviral.2020.104815_bib105) 2010; 51 Hill (10.1016/j.antiviral.2020.104815_bib32) 2018; 4 Reddy (10.1016/j.antiviral.2020.104815_bib75) 2008; 51 Lu (10.1016/j.antiviral.2020.104815_bib58) 2016; 135 Slusarczyk (10.1016/j.antiviral.2020.104815_bib82) 2018; 26 (10.1016/j.antiviral.2020.104815_bib7) 2010; 14 Lai (10.1016/j.antiviral.2020.104815_bib44) 2014; 63 Anderson (10.1016/j.antiviral.2020.104815_bib5) 2009; 45 Cheng (10.1016/j.antiviral.2020.104815_bib19) 2012; 1 Coffin (10.1016/j.antiviral.2020.104815_bib22) 2011; 18 |
| References_xml | – volume: 1 start-page: 185 year: 2016 end-page: 195 ident: bib16 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial publication-title: Lancet Gastroenterol. Hepatol. contributor: fullname: Investigators – year: 2020 ident: bib37 article-title: Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis publication-title: Hepatol. Int. contributor: fullname: Yin – volume: 15 start-page: 5878 year: 2010 end-page: 5908 ident: bib39 article-title: Discovery and development of anti-HBV agents and their resistance publication-title: Molecules contributor: fullname: Seong – volume: 21 start-page: 1956 year: 2014 end-page: 1967 ident: bib15 article-title: Recent progress in the research of small molecule HIV-1 RNase H inhibitors publication-title: Curr. Med. Chem. contributor: fullname: Liu – volume: 9 year: 2013 ident: bib85 article-title: The hepatitis B virus ribonuclease h is sensitive to inhibitors of the human immunodeficiency virus ribonuclease h and integrase enzymes publication-title: PLoS Pathog. contributor: fullname: Sarafianos – volume: 62 start-page: 533 year: 2015 end-page: 540 ident: bib1 article-title: Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection publication-title: J. Hepatol. contributor: fullname: Foster – volume: 1 start-page: 196 year: 2016 end-page: 206 ident: bib11 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial publication-title: Lancet Gastroenterol. Hepatol. contributor: fullname: Investigators – volume: 59 start-page: 3563 year: 2015 end-page: 3569 ident: bib66 article-title: Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy publication-title: Antimicrob. Agents Chemother. contributor: fullname: Ray – volume: 44 start-page: S274 year: 2006 ident: bib47 article-title: 741 Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study publication-title: J. Hepatol. contributor: fullname: Lee – volume: 11 year: 2018 ident: bib12 article-title: Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence publication-title: Therap. Adv. Gastroenterol. contributor: fullname: Agarwal – volume: 51 start-page: 767 year: 2010 end-page: 776 ident: bib105 article-title: Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease publication-title: Hepatology contributor: fullname: Lai – volume: 132 start-page: 1574 year: 2007 end-page: 1585 ident: bib31 article-title: Drug targets and molecular mechanisms of drug resistance in chronic hepatitis publication-title: BMC Gastroenterol. contributor: fullname: Liang – volume: 68 start-page: 3536 year: 1994 end-page: 3543 ident: bib86 article-title: Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer publication-title: J. Virol. contributor: fullname: Ganem – volume: 132 start-page: 186 year: 2016 end-page: 195 ident: bib91 article-title: Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors publication-title: Antivir. Res. contributor: fullname: Tavis – volume: 10 start-page: 779 year: 2016 end-page: 788 ident: bib112 article-title: Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure publication-title: Hepatol. Int. contributor: fullname: Mach – volume: 53 start-page: 3803 year: 2009 end-page: 3814 ident: bib63 article-title: Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis publication-title: B. Antimicrob. Agents Chemother. contributor: fullname: Oberg – volume: 14 start-page: 37 year: 2010 ident: bib7 article-title: Agenix, IMB to develop Hep B drug in China publication-title: Asia Pac. Biotech. News – volume: 137 start-page: 1593 year: 2009 end-page: 1608 ident: bib113 article-title: Hepatitis B virus resistance to nucleos(t)ide analogues publication-title: Gastroenterology contributor: fullname: Locarnini – volume: 18 start-page: 415 year: 2011 end-page: 423 ident: bib22 article-title: Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy publication-title: J. Viral Hepat. contributor: fullname: Terrault – volume: 13 start-page: 239 year: 2016 end-page: 248 ident: bib76 article-title: Global strategies are required to cure and eliminate HBV infection publication-title: Nat. Rev. Gastroenterol. Hepatol. contributor: fullname: Zoulim – year: 2013 ident: bib20 article-title: Phase 3 study of besifovir publication-title: Clin. Trials.gov – volume: 143 start-page: 205 year: 2017 end-page: 217 ident: bib29 article-title: Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles publication-title: Antivir. Res. contributor: fullname: Tavis – volume: 26 start-page: 1 year: 2018 end-page: 31 ident: bib82 article-title: Phosphoramidates and phosphonamidates (ProTides) with antiviral activity publication-title: Antivir. Chem. Chemother. contributor: fullname: Pertusati – volume: 10 start-page: 854 year: 2016 end-page: 860 ident: bib88 article-title: Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia publication-title: Hepatol. Int. contributor: fullname: Jia – volume: 61 year: 2017 ident: bib55 article-title: Synergistic interactions between hepatitis B virus RNase H antagonists and other inhibitors publication-title: Antimicrob. Agents Chemother. contributor: fullname: Tavis – volume: 11 start-page: S147 year: 2017 ident: bib18 article-title: Pharmacokinetics, safety and tolerability of CMX157, a novelprodrug of tenofovir, administered as ascending multiple dosesto healthy volunteers and HBV-infected subjects publication-title: Hepatol. Int contributor: fullname: Sullivan-Bolyai – volume: 20 start-page: 7707 year: 2014 end-page: 7717 ident: bib94 article-title: Emerging antivirals for the treatment of hepatitis B publication-title: World J. Gastroenterol. contributor: fullname: Chen – volume: 15 start-page: 235 year: 2010 end-page: 241 ident: bib46 article-title: Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B publication-title: Antivir. Ther. contributor: fullname: Ahn – volume: 45 start-page: 331 year: 2009 end-page: 350 ident: bib5 article-title: Clevudine for hepatitis B publication-title: Drugs Today contributor: fullname: Anderson – volume: 62 start-page: 526 year: 2015 end-page: 532 ident: bib104 article-title: Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study publication-title: J. Hepatol. contributor: fullname: Han – volume: 17 start-page: 1850 year: 2019 end-page: 1859 ident: bib2 article-title: Efficacy and safety of besifovir dipivoxyl maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection publication-title: Clin. Gastroenterol. Hepatol. contributor: fullname: Han – volume: 67 start-page: 1127 year: 2017 end-page: 1131 ident: bib4 article-title: A research agenda for curing chronic hepatitis B virus infection publication-title: Hepatology contributor: fullname: Zoulim – volume: 67 start-page: 370 year: 2017 end-page: 398 ident: bib28 article-title: Clinical Practice Guidelines on the management of hepatitis B virus infection publication-title: J. Hepatol. contributor: fullname: EASL – volume: 103 start-page: 71 year: 2014 end-page: 77 ident: bib93 article-title: Efficacy of 2 years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment publication-title: Antivir. Res. contributor: fullname: Wang – volume: 61 year: 2017 ident: bib35 article-title: 3-Hydroxypyrimidine-2,4-Diones as novel hepatitis B virus antivirals targeting the viral ribonuclease publication-title: H. Antimicrob. Agents Chemother. contributor: fullname: Sarafianos – volume: 105 start-page: 989 year: 2010 end-page: 1004 ident: bib64 article-title: Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop publication-title: Am. J. Gastroenterol. contributor: fullname: Jacobson – year: 2020 ident: bib21 article-title: A phase 1 double-blinded study for safety, tolerability, pharmacokinetics, and antiviral activity of ATI-2173 in healthy subjects and subjects with chronic hepatitis B virus infection publication-title: Clin. Trials.gov – volume: 38 start-page: 977 year: 2018 end-page: 1002 ident: bib80 article-title: 2'-Fluoro-6'-methylene carbocyclic adenosine and its phosphoramidate prodrug: a novel anti-HBV agent, active against drug-resistant HBV mutants publication-title: Med. Res. Rev. contributor: fullname: Chu – volume: 174 start-page: 104693 year: 2020 ident: bib106 article-title: Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection publication-title: Antivir. Res. contributor: fullname: Ding – volume: 66 start-page: 275 year: 2017 end-page: 281 ident: bib45 article-title: Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B publication-title: J. Hepatol. contributor: fullname: Ip – volume: 252 start-page: 88 year: 1991 end-page: 95 ident: bib23 article-title: Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase publication-title: Science contributor: fullname: Matthews – volume: 57 start-page: 141 year: 2014 end-page: 150 ident: bib43 article-title: Genotypes and genetic variability of hepatitis B virus publication-title: Intervirology contributor: fullname: Kramvis – volume: 54 start-page: 2070 year: 2010 end-page: 2077 ident: bib97 article-title: Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus publication-title: Antimicrob. Agents Chemother. contributor: fullname: Jiang – volume: 51 start-page: 3505 year: 2007 end-page: 3509 ident: bib70 article-title: Evaluation of hexadecyloxypropyl-9-R-[2-phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections publication-title: Antimicrob. Agents Chemother. contributor: fullname: Hostetler – volume: 3 start-page: 15125 year: 2018 end-page: 15133 ident: bib14 article-title: Synthesis and evaluation of troponoids as a new class of antibiotics publication-title: ACS Omega contributor: fullname: Tavis – volume: 3 start-page: 383 year: 2018 end-page: 403 ident: bib74 article-title: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study publication-title: Lancet Gastroenterol. Hepatol. – year: 2017 ident: bib25 article-title: International Patent WO2017223421 A1 contributor: fullname: Bluemling – volume: 11 start-page: 390 year: 2017 end-page: 400 ident: bib26 article-title: Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects publication-title: Hepatol. Int. contributor: fullname: Niu – volume: 18 start-page: 548 year: 2019 end-page: 550 ident: bib103 article-title: How do we determine whether a functional cure for HBV infection has been achieved publication-title: Clin. Gastroenterol. Hepatol. contributor: fullname: Lok – volume: 31 start-page: 6852 year: 2003 end-page: 6859 ident: bib41 article-title: Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors publication-title: Nucleic Acids Res. contributor: fullname: Martin – volume: 13 start-page: 263 year: 2008 end-page: 269 ident: bib68 article-title: Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes publication-title: Antivir. Ther. contributor: fullname: Furman – volume: 24 start-page: 68 year: 2017 end-page: 74 ident: bib52 article-title: No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment publication-title: J. Viral Hepat. contributor: fullname: Gane – volume: 10 start-page: 459 year: 2013 end-page: 466 ident: bib8 article-title: Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340 publication-title: Mol. Pharm. contributor: fullname: Ray – year: 2019 ident: bib99 article-title: About Viral Hepatitis contributor: fullname: World Health Organization – volume: 359 start-page: 2442 year: 2008 end-page: 2455 ident: bib61 article-title: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B publication-title: N. Engl. J. Med. contributor: fullname: Rousseau – volume: 21 start-page: 12558 year: 2015 end-page: 12575 ident: bib59 article-title: Hepatitis B virus therapy: what's the future holding us publication-title: World J. Gastroenterol. contributor: fullname: Ashraf – volume: 164 start-page: 70 year: 2019 end-page: 80 ident: bib30 article-title: Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors publication-title: Antivir. Res. contributor: fullname: Tavis – volume: 44 start-page: 1060 year: 2012 end-page: 1071 ident: bib62 article-title: Antiviral therapies: focus on hepatitis B reverse transcriptase publication-title: Int. J. Biochem. Cell Biol. contributor: fullname: Sarafianos – volume: 99 start-page: 221 year: 2013 end-page: 229 ident: bib34 article-title: beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity publication-title: Antivir. Res. contributor: fullname: Tavis – volume: 6 start-page: 384 year: 2014 end-page: 393 ident: bib78 article-title: Clinical impact of occult hepatitis B virus infection in immunosuppressed patients publication-title: World J. Hepatol. contributor: fullname: Coppola – volume: 11 start-page: 1004 year: 2013 end-page: 1010 ident: bib98 article-title: Reduction of hepatitis B surface antigen and covalently cosed circuar DNA by nucleos(t)ide analogues of different potency publication-title: Clin. Gastroenterol. Hepatol. contributor: fullname: Yuen – volume: 55 start-page: 496 year: 2020 end-page: 514 ident: bib24 article-title: Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review publication-title: J. Gastroenterol. contributor: fullname: Ono – volume: 135 start-page: 24 year: 2016 end-page: 30 ident: bib58 article-title: Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors publication-title: Antivir. Res. contributor: fullname: Tavis – volume: 50 start-page: 2926 year: 2006 end-page: 2931 ident: bib50 article-title: Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer publication-title: Antimicrob. Agents Chemother. contributor: fullname: Yeh – volume: 381 start-page: 468 year: 2013 end-page: 475 ident: bib60 article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study publication-title: Lancet contributor: fullname: Heathcote – volume: 4 start-page: 545 year: 2019 end-page: 558 ident: bib77 article-title: A global scientific strategy to cure hepatitis B publication-title: Lancet Gastroenterol. Hepatol. contributor: fullname: Zoulim – volume: 26 start-page: 1527 year: 2011 end-page: 1535 ident: bib84 article-title: Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir publication-title: J. Gastroenterol. Hepatol. contributor: fullname: Reesink – volume: 51 start-page: 422 year: 2010 end-page: 430 ident: bib17 article-title: Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B publication-title: Hepatology contributor: fullname: Iloeje – volume: 82 start-page: 2305 year: 2008 end-page: 2312 ident: bib51 article-title: Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds publication-title: J. Virol. contributor: fullname: Hu – volume: 63 start-page: 284 year: 2016 end-page: 306 ident: bib53 article-title: Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis publication-title: Hepatology contributor: fullname: Mohammed – volume: 13 start-page: 348 year: 2017 end-page: 356 ident: bib73 article-title: New direct-acting antiviral agents and immunomodulators for hepatitis B virus infection publication-title: Gastroenterol. Hepatol. contributor: fullname: Locarnini – volume: 32 start-page: 1857 year: 2017 end-page: 1860 ident: bib72 article-title: Clevudine induced mitochondrial pyopathy publication-title: J. Kor. Med. Sci. contributor: fullname: Lee – volume: 63 start-page: 261 year: 2016 end-page: 283 ident: bib87 article-title: AASLD guidelines for treatment of chronic hepatitis B publication-title: Hepatology contributor: fullname: Murad – volume: 8 start-page: 682 year: 2007 end-page: 690 ident: bib89 article-title: Pradefovir, a liver-targeted prodrug of adefovir against HBV infection publication-title: Curr. Opin. Invest. Drugs contributor: fullname: Tillmann – volume: 61 year: 2017 ident: bib27 article-title: Troponoids can inhibit growth of the human fungal pathogen Cryptococcus neoformans publication-title: Antimicrob. Agents Chemother. contributor: fullname: Murelli – volume: 4 start-page: 72 year: 2018 end-page: 79 ident: bib32 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? publication-title: J. Virus Erad. contributor: fullname: Pozniak – volume: 36 start-page: 1108 year: 2016 end-page: 1115 ident: bib71 article-title: Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study publication-title: Liver Int. contributor: fullname: Yoon – volume: 10 start-page: 991 year: 2019 end-page: 995 ident: bib92 article-title: Design, synthesis, and anti-HBV activity of new bis(l-amino acid) ester tenofovir prodrugs publication-title: ACS Med. Chem. Lett. contributor: fullname: Liu – volume: 66 start-page: 1296 year: 2017 end-page: 1313 ident: bib54 article-title: Hepatitis B cure: from discovery to regulatory approval publication-title: Hepatology contributor: fullname: Ghany – volume: 29 start-page: 403 year: 1982 end-page: 415 ident: bib83 article-title: Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate publication-title: Cell contributor: fullname: Mason – volume: 64 start-page: S17 year: 2016 end-page: S31 ident: bib3 article-title: Experimental in vitro and in vivo models for the study of human hepatitis B virus infection publication-title: J. Hepatol. contributor: fullname: Dandri – volume: 64 start-page: 1 year: 2004 end-page: 15 ident: bib111 article-title: Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection publication-title: Antivir. Res. contributor: fullname: Zoulim – volume: 17 start-page: 4 year: 2016 end-page: 16 ident: bib6 article-title: The role of tenofovir alafenamide in future HIV management publication-title: HIV Med. contributor: fullname: Di Perri – volume: 19 start-page: 687 year: 2014 end-page: 692 ident: bib9 article-title: Tenofovir alafenamide is not a substrate for renal organion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity publication-title: Antivir. Ther. contributor: fullname: Cihlar – volume: 33 start-page: 111 year: 2013 end-page: 115 ident: bib48 article-title: Impact of therapy on the outcome of chronic hepatitis B publication-title: Liver Int. contributor: fullname: Liaw – volume: 84 start-page: 752 year: 2019 end-page: 759 ident: bib81 article-title: Synthesis of an anti-hepatitis B agent, 2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA) and its phosphoramidate (FMCAP) publication-title: J. Org. Chem. contributor: fullname: Chu – volume: 384 start-page: 2053 year: 2014 end-page: 2063 ident: bib90 article-title: Hepatitis B virus infection publication-title: Lancet contributor: fullname: Lok – volume: 1 start-page: 65 year: 2012 end-page: 73 ident: bib19 article-title: Regulation mechanism of HBV cccDNA publication-title: Infect. Int. contributor: fullname: Wang – volume: 63 start-page: 996 year: 2014 end-page: 1004 ident: bib44 article-title: Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B publication-title: Gut contributor: fullname: Yuen – volume: 13 start-page: 665 year: 2019 end-page: 673 ident: bib49 article-title: Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift publication-title: Hepatol. Int. contributor: fullname: Liaw – volume: 8 start-page: 9633 year: 2018 ident: bib69 article-title: Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil publication-title: Sci. Rep. contributor: fullname: Cusack – volume: 59 start-page: 1070 year: 2015 end-page: 1079 ident: bib57 article-title: Hydroxylated tropolones inhibit hepatitis B virus replication by blocking the viral ribonuclease H activity publication-title: Antimicrob. Agents Chemother. contributor: fullname: Tavis – volume: 66 start-page: 2013 year: 2017 end-page: 2023 ident: bib10 article-title: Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B publication-title: Gut contributor: fullname: Revill – volume: 51 start-page: 666 year: 2008 end-page: 676 ident: bib75 article-title: Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B publication-title: J. Med. Chem. contributor: fullname: Erion – volume: 108 start-page: 48 year: 2014 end-page: 55 ident: bib13 article-title: Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity publication-title: Antivir. Res. contributor: fullname: Tavis – volume: 57 start-page: 4181 year: 2013 end-page: 4189 ident: bib38 article-title: Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine publication-title: Antimicrob. Agents Chemother. contributor: fullname: Hu – volume: 69 start-page: 1231 year: 2018 end-page: 1241 ident: bib42 article-title: Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels publication-title: J. Hepatol. contributor: fullname: Protzer – volume: 149 start-page: 41 year: 2018 end-page: 47 ident: bib56 article-title: Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice publication-title: Antivir. Res. contributor: fullname: Tavis – start-page: 2185 year: 2013 end-page: 2221 ident: bib79 article-title: Hepadnaviruses publication-title: Fields Virology contributor: fullname: Mason – volume: 1 start-page: 521 year: 2012 end-page: 541 ident: bib36 article-title: Inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H activity publication-title: Biology contributor: fullname: Parniak – volume: 683 start-page: 10 year: 2012 end-page: 15 ident: bib109 article-title: activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates publication-title: Eur. J. Pharmacol. contributor: fullname: Wang – volume: 55 start-page: 441 year: 2019 end-page: 452 ident: bib67 article-title: Non-nucleoside hepatitis B virus polymerase inhibitors identified by an publication-title: J. Gastroenterol. contributor: fullname: Toyoda – volume: 14 start-page: 439 year: 2018 end-page: 442 ident: bib40 article-title: Advances in hepatology: emerging therapies toward a functional cure for hepatitis B virus infection publication-title: Gastroenterol. Hepatol. contributor: fullname: Kim – volume: 60 start-page: 177 year: 2014 end-page: 189 ident: bib65 article-title: Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function publication-title: Minerva Gastroenterol. Dietol. contributor: fullname: Atta – year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib99 contributor: fullname: World Health Organization – volume: 61 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib35 article-title: 3-Hydroxypyrimidine-2,4-Diones as novel hepatitis B virus antivirals targeting the viral ribonuclease publication-title: H. Antimicrob. Agents Chemother. contributor: fullname: Huber – volume: 1 start-page: 65 year: 2012 ident: 10.1016/j.antiviral.2020.104815_bib19 article-title: Regulation mechanism of HBV cccDNA publication-title: Infect. Int. doi: 10.1515/ii-2017-0010 contributor: fullname: Cheng – volume: 103 start-page: 71 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib93 article-title: Efficacy of 2 years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2014.01.009 contributor: fullname: Wang – volume: 29 start-page: 403 year: 1982 ident: 10.1016/j.antiviral.2020.104815_bib83 article-title: Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate publication-title: Cell doi: 10.1016/0092-8674(82)90157-X contributor: fullname: Summers – volume: 59 start-page: 1070 year: 2015 ident: 10.1016/j.antiviral.2020.104815_bib57 article-title: Hydroxylated tropolones inhibit hepatitis B virus replication by blocking the viral ribonuclease H activity publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.04617-14 contributor: fullname: Lu – volume: 64 start-page: S17 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib3 article-title: Experimental in vitro and in vivo models for the study of human hepatitis B virus infection publication-title: J. Hepatol. doi: 10.1016/j.jhep.2016.02.012 contributor: fullname: Allweiss – volume: 10 start-page: 991 year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib92 article-title: Design, synthesis, and anti-HBV activity of new bis(l-amino acid) ester tenofovir prodrugs publication-title: ACS Med. Chem. Lett. doi: 10.1021/acsmedchemlett.9b00184 contributor: fullname: Wang – volume: 60 start-page: 177 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib65 article-title: Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function publication-title: Minerva Gastroenterol. Dietol. contributor: fullname: Murakami – volume: 55 start-page: 441 year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib67 article-title: Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay publication-title: J. Gastroenterol. doi: 10.1007/s00535-019-01643-0 contributor: fullname: Nakajima – volume: 10 start-page: 459 year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib8 article-title: Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340 publication-title: Mol. Pharm. doi: 10.1021/mp3002045 contributor: fullname: Babusis – volume: 13 start-page: 665 year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib49 article-title: Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift publication-title: Hepatol. Int. doi: 10.1007/s12072-019-09989-6 contributor: fullname: Liaw – ident: 10.1016/j.antiviral.2020.104815_bib102 – volume: 14 start-page: 37 year: 2010 ident: 10.1016/j.antiviral.2020.104815_bib7 article-title: Agenix, IMB to develop Hep B drug in China publication-title: Asia Pac. Biotech. News – volume: 15 start-page: 5878 year: 2010 ident: 10.1016/j.antiviral.2020.104815_bib39 article-title: Discovery and development of anti-HBV agents and their resistance publication-title: Molecules doi: 10.3390/molecules15095878 contributor: fullname: Kim – volume: 17 start-page: 1850 year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib2 article-title: Efficacy and safety of besifovir dipivoxyl maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2018.11.001 contributor: fullname: Ahn – volume: 26 start-page: 1 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib82 article-title: Phosphoramidates and phosphonamidates (ProTides) with antiviral activity publication-title: Antivir. Chem. Chemother. doi: 10.1177/2040206618775243 contributor: fullname: Slusarczyk – volume: 11 start-page: 1004 year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib98 article-title: Reduction of hepatitis B surface antigen and covalently cosed circuar DNA by nucleos(t)ide analogues of different potency publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2013.01.026 contributor: fullname: Wong – volume: 36 start-page: 1108 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib71 article-title: Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study publication-title: Liver Int. doi: 10.1111/liv.13059 contributor: fullname: Park – volume: 51 start-page: 767 year: 2010 ident: 10.1016/j.antiviral.2020.104815_bib105 article-title: Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease publication-title: Hepatology doi: 10.1002/hep.23462 contributor: fullname: Yuen – volume: 143 start-page: 205 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib29 article-title: Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2017.04.012 contributor: fullname: Edwards – volume: 57 start-page: 4181 year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib38 article-title: Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00599-13 contributor: fullname: Jones – volume: 17 start-page: 4 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib6 article-title: The role of tenofovir alafenamide in future HIV management publication-title: HIV Med. doi: 10.1111/hiv.12401 contributor: fullname: Antela – ident: 10.1016/j.antiviral.2020.104815_bib107 – start-page: 2185 year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib79 article-title: Hepadnaviruses contributor: fullname: Seeger – ident: 10.1016/j.antiviral.2020.104815_bib100 – volume: 84 start-page: 752 year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib81 article-title: Synthesis of an anti-hepatitis B agent, 2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA) and its phosphoramidate (FMCAP) publication-title: J. Org. Chem. doi: 10.1021/acs.joc.8b02599 contributor: fullname: Singh – volume: 44 start-page: S274 year: 2006 ident: 10.1016/j.antiviral.2020.104815_bib47 article-title: 741 Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study publication-title: J. Hepatol. doi: 10.1016/S0168-8278(06)80742-7 contributor: fullname: Lee – volume: 149 start-page: 41 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib56 article-title: Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2017.11.008 contributor: fullname: Long – ident: 10.1016/j.antiviral.2020.104815_bib108 – volume: 66 start-page: 2013 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib10 article-title: Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B publication-title: Gut doi: 10.1136/gutjnl-2015-309300 contributor: fullname: Bayliss – volume: 67 start-page: 1127 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib4 article-title: A research agenda for curing chronic hepatitis B virus infection publication-title: Hepatology doi: 10.1002/hep.29509 contributor: fullname: Alter – volume: 38 start-page: 977 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib80 article-title: 2'-Fluoro-6'-methylene carbocyclic adenosine and its phosphoramidate prodrug: a novel anti-HBV agent, active against drug-resistant HBV mutants publication-title: Med. Res. Rev. doi: 10.1002/med.21490 contributor: fullname: Singh – volume: 359 start-page: 2442 year: 2008 ident: 10.1016/j.antiviral.2020.104815_bib61 article-title: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0802878 contributor: fullname: Marcellin – volume: 13 start-page: 348 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib73 article-title: New direct-acting antiviral agents and immunomodulators for hepatitis B virus infection publication-title: Gastroenterol. Hepatol. contributor: fullname: Peters – volume: 252 start-page: 88 year: 1991 ident: 10.1016/j.antiviral.2020.104815_bib23 article-title: Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase publication-title: Science doi: 10.1126/science.1707186 contributor: fullname: Davies – volume: 66 start-page: 1296 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib54 article-title: Hepatitis B cure: from discovery to regulatory approval publication-title: Hepatology doi: 10.1002/hep.29323 contributor: fullname: Lok – volume: 26 start-page: 1527 year: 2011 ident: 10.1016/j.antiviral.2020.104815_bib84 article-title: Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/j.1440-1746.2011.06766.x contributor: fullname: Takkenberg – volume: 3 start-page: 15125 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib14 article-title: Synthesis and evaluation of troponoids as a new class of antibiotics publication-title: ACS Omega doi: 10.1021/acsomega.8b01754 contributor: fullname: Cao – ident: 10.1016/j.antiviral.2020.104815_bib96 – volume: 11 start-page: 390 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib26 article-title: Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects publication-title: Hepatol. Int. doi: 10.1007/s12072-017-9797-y contributor: fullname: Ding – volume: 164 start-page: 70 year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib30 article-title: Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2019.02.005 contributor: fullname: Edwards – year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib20 article-title: Phase 3 study of besifovir publication-title: Clin. Trials.gov – volume: 108 start-page: 48 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib13 article-title: Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2014.05.007 contributor: fullname: Cai – volume: 51 start-page: 666 year: 2008 ident: 10.1016/j.antiviral.2020.104815_bib75 article-title: Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B publication-title: J. Med. Chem. doi: 10.1021/jm7012216 contributor: fullname: Reddy – volume: 53 start-page: 3803 year: 2009 ident: 10.1016/j.antiviral.2020.104815_bib63 article-title: Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis publication-title: B. Antimicrob. Agents Chemother. doi: 10.1128/AAC.00263-09 contributor: fullname: Michalak – volume: 82 start-page: 2305 year: 2008 ident: 10.1016/j.antiviral.2020.104815_bib51 article-title: Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds publication-title: J. Virol. doi: 10.1128/JVI.02147-07 contributor: fullname: Lin – volume: 8 start-page: 682 year: 2007 ident: 10.1016/j.antiviral.2020.104815_bib89 article-title: Pradefovir, a liver-targeted prodrug of adefovir against HBV infection publication-title: Curr. Opin. Invest. Drugs contributor: fullname: Tillmann – volume: 1 start-page: 185 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib16 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(16)30024-3 contributor: fullname: Chan – volume: 50 start-page: 2926 year: 2006 ident: 10.1016/j.antiviral.2020.104815_bib50 article-title: Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01566-05 contributor: fullname: Lin – volume: 32 start-page: 1857 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib72 article-title: Clevudine induced mitochondrial pyopathy publication-title: J. Kor. Med. Sci. doi: 10.3346/jkms.2017.32.11.1857 contributor: fullname: Park – volume: 11 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib12 article-title: Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence publication-title: Therap. Adv. Gastroenterol. doi: 10.1177/1756284818786108 contributor: fullname: Byrne – volume: 683 start-page: 10 year: 2012 ident: 10.1016/j.antiviral.2020.104815_bib109 article-title: In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2012.02.030 contributor: fullname: Zhou – volume: 33 start-page: 111 issue: Suppl. 1 year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib48 article-title: Impact of therapy on the outcome of chronic hepatitis B publication-title: Liver Int. doi: 10.1111/liv.12057 contributor: fullname: Liaw – volume: 15 start-page: 235 year: 2010 ident: 10.1016/j.antiviral.2020.104815_bib46 article-title: Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B publication-title: Antivir. Ther. doi: 10.3851/IMP1510 contributor: fullname: Lee – volume: 13 start-page: 239 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib76 article-title: Global strategies are required to cure and eliminate HBV infection publication-title: Nat. Rev. Gastroenterol. Hepatol. doi: 10.1038/nrgastro.2016.7 contributor: fullname: Revill – volume: 54 start-page: 2070 year: 2010 ident: 10.1016/j.antiviral.2020.104815_bib97 article-title: Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01764-09 contributor: fullname: Wang – volume: 51 start-page: 422 year: 2010 ident: 10.1016/j.antiviral.2020.104815_bib17 article-title: Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B publication-title: Hepatology doi: 10.1002/hep.23327 contributor: fullname: Chang – volume: 13 start-page: 263 year: 2008 ident: 10.1016/j.antiviral.2020.104815_bib68 article-title: Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes publication-title: Antivir. Ther. doi: 10.1177/135965350801300206 contributor: fullname: Niu – volume: 31 start-page: 6852 year: 2003 ident: 10.1016/j.antiviral.2020.104815_bib41 article-title: Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkg881 contributor: fullname: Klumpp – volume: 3 start-page: 383 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib74 article-title: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(18)30056-6 – volume: 19 start-page: 687 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib9 article-title: Tenofovir alafenamide is not a substrate for renal organion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity publication-title: Antivir. Ther. doi: 10.3851/IMP2770 contributor: fullname: Bam – volume: 21 start-page: 12558 year: 2015 ident: 10.1016/j.antiviral.2020.104815_bib59 article-title: Hepatitis B virus therapy: what's the future holding us publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v21.i44.12558 contributor: fullname: Manzoor – volume: 10 start-page: 779 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib112 article-title: Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure publication-title: Hepatol. Int. doi: 10.1007/s12072-016-9737-2 contributor: fullname: Zoulim – volume: 137 start-page: 1593 year: 2009 ident: 10.1016/j.antiviral.2020.104815_bib113 article-title: Hepatitis B virus resistance to nucleos(t)ide analogues publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.08.063 contributor: fullname: Zoulim – volume: 8 start-page: 9633 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib69 article-title: Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil publication-title: Sci. Rep. doi: 10.1038/s41598-018-27890-4 contributor: fullname: Omoto – volume: 63 start-page: 996 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib44 article-title: Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B publication-title: Gut doi: 10.1136/gutjnl-2013-305138 contributor: fullname: Lai – volume: 62 start-page: 533 year: 2015 ident: 10.1016/j.antiviral.2020.104815_bib1 article-title: Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection publication-title: J. Hepatol. doi: 10.1016/j.jhep.2014.10.035 contributor: fullname: Agarwal – volume: 57 start-page: 141 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib43 article-title: Genotypes and genetic variability of hepatitis B virus publication-title: Intervirology doi: 10.1159/000360947 contributor: fullname: Kramvis – volume: 62 start-page: 526 year: 2015 ident: 10.1016/j.antiviral.2020.104815_bib104 article-title: Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study publication-title: J. Hepatol. doi: 10.1016/j.jhep.2014.10.026 contributor: fullname: Yuen – volume: 6 start-page: 384 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib78 article-title: Clinical impact of occult hepatitis B virus infection in immunosuppressed patients publication-title: World J. Hepatol. doi: 10.4254/wjh.v6.i6.384 contributor: fullname: Sagnelli – volume: 20 start-page: 7707 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib94 article-title: Emerging antivirals for the treatment of hepatitis B publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v20.i24.7707 contributor: fullname: Wang – volume: 64 start-page: 1 year: 2004 ident: 10.1016/j.antiviral.2020.104815_bib111 article-title: Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2004.07.003 contributor: fullname: Zoulim – volume: 44 start-page: 1060 year: 2012 ident: 10.1016/j.antiviral.2020.104815_bib62 article-title: Antiviral therapies: focus on hepatitis B reverse transcriptase publication-title: Int. J. Biochem. Cell Biol. doi: 10.1016/j.biocel.2012.04.006 contributor: fullname: Michailidis – volume: 1 start-page: 521 year: 2012 ident: 10.1016/j.antiviral.2020.104815_bib36 article-title: Inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H activity publication-title: Biology doi: 10.3390/biology1030521 contributor: fullname: Ilina – volume: 67 start-page: 370 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib28 article-title: Clinical Practice Guidelines on the management of hepatitis B virus infection publication-title: J. Hepatol. doi: 10.1016/j.jhep.2017.03.021 contributor: fullname: EASL – volume: 174 start-page: 104693 year: 2020 ident: 10.1016/j.antiviral.2020.104815_bib106 article-title: Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2019.104693 contributor: fullname: Zhang – volume: 105 start-page: 989 year: 2010 ident: 10.1016/j.antiviral.2020.104815_bib64 article-title: Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop publication-title: Am. J. Gastroenterol. doi: 10.1038/ajg.2009.726 contributor: fullname: Monto – volume: 381 start-page: 468 year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib60 article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study publication-title: Lancet doi: 10.1016/S0140-6736(12)61425-1 contributor: fullname: Marcellin – volume: 68 start-page: 3536 year: 1994 ident: 10.1016/j.antiviral.2020.104815_bib86 article-title: Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer publication-title: J. Virol. doi: 10.1128/JVI.68.6.3536-3543.1994 contributor: fullname: Tavis – volume: 132 start-page: 186 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib91 article-title: Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2016.06.005 contributor: fullname: Villa – volume: 1 start-page: 196 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib11 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(16)30107-8 contributor: fullname: Buti – volume: 63 start-page: 284 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib53 article-title: Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis publication-title: Hepatology doi: 10.1002/hep.28280 contributor: fullname: Lok – volume: 9 year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib85 article-title: The hepatitis B virus ribonuclease h is sensitive to inhibitors of the human immunodeficiency virus ribonuclease h and integrase enzymes publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1003125 contributor: fullname: Tavis – ident: 10.1016/j.antiviral.2020.104815_bib110 – volume: 10 start-page: 854 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib88 article-title: Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia publication-title: Hepatol. Int. doi: 10.1007/s12072-016-9745-2 contributor: fullname: Tian – volume: 18 start-page: 415 year: 2011 ident: 10.1016/j.antiviral.2020.104815_bib22 article-title: Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy publication-title: J. Viral Hepat. doi: 10.1111/j.1365-2893.2010.01321.x contributor: fullname: Coffin – volume: 69 start-page: 1231 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib42 article-title: Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels publication-title: J. Hepatol. doi: 10.1016/j.jhep.2018.08.012 contributor: fullname: Ko – volume: 384 start-page: 2053 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib90 article-title: Hepatitis B virus infection publication-title: Lancet doi: 10.1016/S0140-6736(14)60220-8 contributor: fullname: Trepo – volume: 59 start-page: 3563 year: 2015 ident: 10.1016/j.antiviral.2020.104815_bib66 article-title: Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00128-15 contributor: fullname: Murakami – volume: 4 start-page: 545 year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib77 article-title: A global scientific strategy to cure hepatitis B publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(19)30119-0 contributor: fullname: Revill – year: 2020 ident: 10.1016/j.antiviral.2020.104815_bib21 article-title: A phase 1 double-blinded study for safety, tolerability, pharmacokinetics, and antiviral activity of ATI-2173 in healthy subjects and subjects with chronic hepatitis B virus infection publication-title: Clin. Trials.gov – volume: 21 start-page: 1956 year: 2014 ident: 10.1016/j.antiviral.2020.104815_bib15 article-title: Recent progress in the research of small molecule HIV-1 RNase H inhibitors publication-title: Curr. Med. Chem. doi: 10.2174/0929867321666140120121158 contributor: fullname: Cao – volume: 61 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib55 article-title: Synergistic interactions between hepatitis B virus RNase H antagonists and other inhibitors publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.02441-16 contributor: fullname: Lomonosova – volume: 55 start-page: 496 year: 2020 ident: 10.1016/j.antiviral.2020.104815_bib24 article-title: Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review publication-title: J. Gastroenterol. doi: 10.1007/s00535-020-01680-0 contributor: fullname: de Fraga – volume: 51 start-page: 3505 year: 2007 ident: 10.1016/j.antiviral.2020.104815_bib70 article-title: Evaluation of hexadecyloxypropyl-9-R-[2-phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00460-07 contributor: fullname: Painter – volume: 4 start-page: 72 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib32 article-title: Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? publication-title: J. Virus Erad. doi: 10.1016/S2055-6640(20)30248-X contributor: fullname: Hill – volume: 11 start-page: S147 issue: Suppl. 1 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib18 article-title: Pharmacokinetics, safety and tolerability of CMX157, a novelprodrug of tenofovir, administered as ascending multiple dosesto healthy volunteers and HBV-infected subjects publication-title: Hepatol. Int contributor: fullname: Chatsiricharoenkul – year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib25 contributor: fullname: De La Rosa – volume: 45 start-page: 331 year: 2009 ident: 10.1016/j.antiviral.2020.104815_bib5 article-title: Clevudine for hepatitis B publication-title: Drugs Today doi: 10.1358/dot.2009.45.5.1377596 contributor: fullname: Anderson – volume: 132 start-page: 1574 year: 2007 ident: 10.1016/j.antiviral.2020.104815_bib31 article-title: Drug targets and molecular mechanisms of drug resistance in chronic hepatitis publication-title: BMC Gastroenterol. doi: 10.1053/j.gastro.2007.02.039 contributor: fullname: Ghany – ident: 10.1016/j.antiviral.2020.104815_bib33 – year: 2020 ident: 10.1016/j.antiviral.2020.104815_bib37 article-title: Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis publication-title: Hepatol. Int. doi: 10.1007/s12072-020-10024-2 contributor: fullname: Jia – volume: 18 start-page: 548 year: 2019 ident: 10.1016/j.antiviral.2020.104815_bib103 article-title: How do we determine whether a functional cure for HBV infection has been achieved publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2019.08.033 contributor: fullname: Yip – volume: 66 start-page: 275 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib45 article-title: Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B publication-title: J. Hepatol. doi: 10.1016/j.jhep.2016.08.022 contributor: fullname: Lai – volume: 99 start-page: 221 year: 2013 ident: 10.1016/j.antiviral.2020.104815_bib34 article-title: beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2013.06.007 contributor: fullname: Hu – volume: 63 start-page: 261 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib87 article-title: AASLD guidelines for treatment of chronic hepatitis B publication-title: Hepatology doi: 10.1002/hep.28156 contributor: fullname: Terrault – ident: 10.1016/j.antiviral.2020.104815_bib95 – volume: 14 start-page: 439 year: 2018 ident: 10.1016/j.antiviral.2020.104815_bib40 article-title: Advances in hepatology: emerging therapies toward a functional cure for hepatitis B virus infection publication-title: Gastroenterol. Hepatol. contributor: fullname: Kim – volume: 135 start-page: 24 year: 2016 ident: 10.1016/j.antiviral.2020.104815_bib58 article-title: Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2016.09.009 contributor: fullname: Lu – volume: 61 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib27 article-title: Troponoids can inhibit growth of the human fungal pathogen Cryptococcus neoformans publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.02574-16 contributor: fullname: Donlin – volume: 24 start-page: 68 year: 2017 ident: 10.1016/j.antiviral.2020.104815_bib52 article-title: No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment publication-title: J. Viral Hepat. doi: 10.1111/jvh.12613 contributor: fullname: Liu – ident: 10.1016/j.antiviral.2020.104815_bib101 |
| SSID | ssj0006798 |
| Score | 2.5161934 |
| SecondaryResourceType | review_article |
| Snippet | Chronic Hepatitis B Virus infections afflict >250 million people and kill nearly 1 million annually. Current non-curative therapies are dominated by... |
| SourceID | pubmedcentral proquest crossref pubmed elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 104815 |
| SubjectTerms | Animals Antiviral Agents - pharmacology Chronic hepatitis B Clinical Trials as Topic Hepatitis B virus Hepatitis B virus - drug effects Hepatitis B virus - physiology Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Mice Nucleic Acid Synthesis Inhibitors - pharmacology Nucleos(t)ide analogs Nucleosides - pharmacology Reverse transcriptase inhibitors Ribonuclease H - antagonists & inhibitors Ribonuclease H inhibitors Virus Replication - drug effects |
| Title | HBV replication inhibitors |
| URI | https://dx.doi.org/10.1016/j.antiviral.2020.104815 https://www.ncbi.nlm.nih.gov/pubmed/32380149 https://search.proquest.com/docview/2400549610 https://pubmed.ncbi.nlm.nih.gov/PMC7293572 |
| Volume | 179 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9BJxAvaIyvjg0VibcqUWo7scNbNzINJHhgA-3NchJbyzRlqFsf9t9zV-erKwgQ4iWKnKZ2764_353vA-CtkdwmTkWBVQ4NlFKIQBlrgrgomFClmwmzcl2cyM9n6n0msr6jYD_2XzmNY8hrypz9C253X4oDeI88xytyHa9_xPfjg290END64qZVfV7lFfXUGeqh85q6RixWVf0H_izCSNwnF2b65WpJO6aPE7w0gxhZVLmvmzStw9tFdTk9CHvzvylZsIrHycKhSwHtxzb8tPFzbeS6eNdjkgQ89rWwQuvhUkkWpJHvSdvhqe8Os4HN3k1wEZr2F4Y0Nx0yK5_Reafw9QnNSBMyBCLGqETBFkM4ESPYmn_Izj52Oy6dJPka7n6Fa3F8P53uV1rIppVxN1h2oH2cbsPjxmyYzD2_n8A9W-_AA99I9HYHHn5qQiSewi4KwGQgAJNeAJ7B16Ps9PA4aBpgBIWQ8Q01RzI8cso6yZ1Kc5kzy5kxhZJu5uIycaxUqU1FwdHOJ0BViU1dImzp8sgo_hxG9VVtX8IkmRlrJVcFIrwwVuSoSJdFalniZpScPYaoJYj-7uuc6DYA8EJ3NNREQ-1pOIZ3LeF0o655NUwjx3__8puW1BoBjU6pTG1RgDUFNcciRbV-DC886bsVcVQwyaYfg1xjSvcBKpa-_qSuzldF09GI5LFku_-y6FfwqP-77MHoZrG0-3D_uly-bkTyBy0Ti7A |
| link.rule.ids | 230,315,782,786,887,27934,27935 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HBV+replication+inhibitors&rft.jtitle=Antiviral+research&rft.au=Pierra+Rouviere%2C+Claire&rft.au=Dousson%2C+Cyril+B.&rft.au=Tavis%2C+John+E.&rft.date=2020-07-01&rft.pub=Elsevier+B.V&rft.issn=0166-3542&rft.eissn=1872-9096&rft.volume=179&rft_id=info:doi/10.1016%2Fj.antiviral.2020.104815&rft.externalDocID=S0166354220302291 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0166-3542&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0166-3542&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0166-3542&client=summon |